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Inﬂammation plays vital roles in protective responses against pathogens and tissue repair,
however, improper resolution of inﬂammatory networks is centrally involved in the patho-
genesis ofmany acute and chronic diseases. Extensive advances have beenmade in recent
years to deﬁne the inﬂammatory processes that are required for pathogen clearance, how-
ever, in comparison, less is known about the regulation of inﬂammation in sterile settings.
Over the past decade non-communicable chronic diseases that are potentiated by sterile
inﬂammation have replaced infectious diseases as the major threat to global human health.
Thus, improved understanding of the sterile inﬂammatory process has emerged as one of
the most important areas of biomedical investigation during our time. In this review we
highlight the central role that interleukin-1 family cytokines play in sterile inﬂammatory
diseases.
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INTRODUCTION
Infection and cellular injury are the two principal stimuli that
provoke inﬂammation. Detection of infectious agents and danger
signals by pattern recognition receptors orchestrates a coordinated
series of events that ensure removal of the insult and promote tis-
sue repair. Following recognition of the foreign agents a cascade of
inﬂammatory cytokines are induced that instruct the recruitment
of neutrophils and macrophages to the site of infection or injury.
Once mobilized to the tissue sites neutrophils and macrophages
engulf and contain the insult, and also recruit additional immune
cells to the site of inﬂammation through the production of
cytokines and chemokines. Many of the pathogen-derived fac-
tors that trigger inﬂammation have been formally characterized,
and include conserved molecules that are required for micro-
bial survival. In comparison, sterile activators of inﬂammation
are structurally diverse and can originate from both endoge-
nous and exogenous sources. For instance; mechanical trauma,
hypoxia, metabolic distress, chemical and environmental insults,
and ischemia can all provoke sterile inﬂammation. Emerging
data suggests that man-made and environmental irritants (silica,
asbestos, alum, alloy particles, and car exhaust), metabolic fac-
tors (cholesterol, amyloids, saturated fatty acids, and glucose) and
endogenous danger signals that are released as a result of aber-
rant cell death [ATP, reactive oxygen species (ROSs), uric acid, and
interleukin-1α (IL-1α)] can all trigger sterile inﬂammation (Rock
et al., 2010).
Although inﬂammatory responses play critical roles in the
eradication of pathogens and sterile insults, excessive andunremit-
ting inﬂammation causes damage to healthy tissue and centrally
contributes to disease pathology. Dysregulated production of
cytokines, ROSs, proteases, and growth factors by both innate
and adaptive immune cells can lead to collateral damage and
disrupt tissue homeostasis. Sterile inﬂammation has been impli-
cated in a spectrum of acute and chronic disorders that include
obesity, atherosclerosis, type 2 diabetes, gout, and multiple neu-
rodegenerative diseases (Figure 1). In this review we focus on the
pivotal role of IL-1 family cytokines in various sterile inﬂammatory
diseases.
IL-1 FAMILY CYTOKINES
The IL-1 family of cytokines consists of 11 members that are
centrally involved in regulating inﬂammatory responses to both
infections and sterile insults. IL-1 family cytokines include IL-1α,
IL-1β, IL-1Ra, IL-18, IL-33, IL-36Ra, IL-36α, IL-37, IL-36β, IL-
36γ, and IL-38 (Dinarello, 2011). In this review we speciﬁcally
focus on the roles of IL-1α, IL-1β, IL-18, and IL-33 in ster-
ile inﬂammatory disease as these cytokines have been described
to signiﬁcantly inﬂuence disease pathogenesis. The emerging
roles of the other IL-1 family cytokines in biology are beyond
the scope of this review and are described in detail elsewhere
(Dinarello, 2010).
Interleukin-1 has been shown to promote sterile inﬂamma-
tory disease pathogenesis at multiple levels. For example, IL-1
can directly cause tissue destruction, altered ﬁbroblast prolifera-
tion, and collagen deposition (Schmidt et al., 1984; Zucali et al.,
1986; Ishida et al., 2006; Steer et al., 2006). Moreover, IL-1 recep-
tor (IL-1R) signaling potently induces the productionof secondary
inﬂammatory cytokines and chemokines such as IL-6, TNFα, KC,
and G-CSF (Di Paolo et al., 2009; Orjalo et al., 2009). IL-1 also
contributes to the perpetuation of inﬂammatory disease by pro-
moting the induction of pathogenic cytokines (IFN-γ, IL-17, and
GM-CSF) by T cells and innate effector cells (Sutton et al., 2009;
Lukens et al., 2012). Much like IL-1, IL-18 has also been shown
to stimulate proinﬂammatory signaling and has historically been
classiﬁed as a potent inducer of IFN-γ production. Likewise, IL-
18 also promotes the activation and recruitment of inﬂammatory
immune cells including macrophages, neutrophils, natural killer
(NK) cells, and T cells (Nakanishi et al., 2001; Dinarello, 2007).
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FIGURE 1 | Sterile inflammatory diseases. Sterile inﬂammatory diseases can affect multiple organ systems and are a major threat to global human health.
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IL-33 is one of the newest members of the IL-1 cytokine super-
family and its roles in inﬂammatory disease are just now being
uncovered (Liew et al., 2010). Engagement of the ST2 receptor
by IL-33 provokes the induction of T helper 2 (Th2) cytokines
including IL-5 and IL-13, and thus IL-33 uniquely contributes to
the pathogenesis of Th2-mediated inﬂammatory diseases. Below
we describe the molecular mechanisms that control the release
of these potent cytokines and highlight emerging data that sug-
gest central roles for IL-1 family cytokines in sterile inﬂammatory
diseases.
INFLAMMASOME-DERIVED IL-1β AND IL-18
Over the past decade extensive research from various groups has
shed light on the ability of inﬂammasome complexes to regulate
the processing and activation of IL-1β and IL-18. Inﬂammasomes
are comprised of a Nod-like receptor (NLR) or a pyrin- and HIN-
200 domain-containing protein (PYHIN), an adaptor protein, and
caspase-1 (Figure 2). NLRs are sensor molecules that detect both
pathogen- and danger-associated molecular patterns (PAMPs and
DAMPs, respectively). Activation of NLR proteins promotes the
recruitment of the inﬂammasome-adaptor protein, ASC (also
known as PYCARD), and pro-caspase-1 into a molecular plat-
formknownas the inﬂammasome. Thesemulti-protein complexes
mediate the proximity-induced autoactivation of caspase-1. Active
caspase-1 subsequently cleaves pro-IL-1β and pro-IL-18, which is
required for their secretion and to elicit their inﬂammatory prop-
erties. The activation of inﬂammasomes can occur in response
to an array of different stimuli. For instance, inﬂammasome-
mediated recognition of pathogen-derived molecules is a critical
ﬁrst line of defense during infection (Kanneganti et al., 2006;
Kanneganti, 2010; Lupfer and Kanneganti, 2012). On the other
hand, inﬂammasomes are also involved in the detection of danger-
and stress-associated signals that are generated during sterile
inﬂammation. Sterile stimuli that trigger inﬂammasome activa-
tion include endogenous danger signals that are released during
aberrant cell death (ATP and uric acid), metabolic factors (satu-
rated fatty acids and cholesterol crystals), and exogenous irritants
(asbestos and silica; Figure 2). Mutations in NLR-inﬂammasome
proteins are associatedwithbothmonogenic andpolygenic human
inﬂammatory disorders. Most of these rare genetic disorders are
associated with mutations that result in exacerbated secretion
of inﬂammasome-derived cytokines (Aksentijevich et al., 2007).
Importantly, therapeutics that block IL-1 signaling have proven
successful in the treatment of these disorders (Hoffman et al., 2004;
Church and McDermott, 2009).
INFLAMMASOME-INDEPENDENT SOURCES OF IL-1β
Bioactive IL-1β can also be generated by inﬂammasome-
independent mechanisms, however, the contributions of these
non-canonical sources of IL-1β to the inﬂammatory environ-
ment and disease pathology are poorly understood. Proteases
that are expressed by neutrophils are primarily responsible for
the majority of caspase-1 independent IL-1β. Examples of neu-
trophilic proteases that have been shown to cleave pro-IL-1β
independently of caspase-1 activity include elastase, proteinase-
3, cathepsin G, granzyme A, and chymase (Dinarello, 2011). Roles
for inﬂammasome-independent IL-1β in disease pathogenesis
have only been described in a few settings to date. For instance,
FIGURE 2 | Sterile inflammasome activation. Endogenous, metabolic,
and exogenous danger-associated signals activate NLRP3 in the cytosol.
Detection of danger signals by NLRP3 promotes the recruitment of ASC
and caspase-1 into a multi-protein complex known as the inﬂammasome.
Inﬂammasome formation provides the necessary molecular platform to
promote self-cleavage and activation of caspase-1. Activated caspase-1
cleaves the pro-forms of IL-1β and IL-18, which is required for their secretion
and biological activity. Inﬂammasome-derived IL-1β, and IL-1α that is released
from dying cells bind IL-1R, whereas IL-18 has its own receptor. Engagement
of IL-1R or IL-18R promotes the robust production of secondary
proinﬂammatory molecules (TNFα, IL-6, KC, etc.) that can then trigger
additional immune cell recruitment and activation.
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capase-1 autonomous IL-1β was reported to provoke sterile
inﬂammation in models of urate crystal-induced peritonitis and
joint damage (Guma et al., 2009; Joosten et al., 2009). Cell death
that ensues in sterile inﬂammatory environments results in the
passive release of inactive pro-IL-1β. Extracellular pro-IL-1β
can then be cleaved and activated by activated neutrophils that
express surface-bound proteases (Netea et al., 2010). As most ster-
ile inﬂammatory diseases are associated with enhanced neutrophil
recruitment and tissue damage, it is likely that protease-dependent
activation of IL-1β is involved in pathogenesis at some level. One
possible scenario is that inﬂammasomes are involved in the ini-
tial sensing of the sterile threat and that caspase-1 independent
sources of IL-1β are important in perpetuating the inﬂamma-
tory environment later in the response. Regardless, it is clear that
additional studies are needed to elucidate the unique contribu-
tions of inﬂammasome-independent sources of IL-1β in sterile
disease.
IL-1α RELEASE
Historically, IL-1α and IL-1β have been believed to possess over-
lapping biological functions. Indeed, it is true that recombinant
IL-1α and IL-1β both bind to IL-1R to induce a proinﬂamma-
tory signaling cascade. However, several lines of evidence point
to distinct biological roles for IL-1α. For one, IL-1α belongs to a
family of “dual function cytokines”, which can exert distinct bio-
logical functions in the nucleus and also when released into the
extracellular compartment. The nuclear location sequence in the
N-terminus of IL-1α allows it to translocate to the nucleus where it
affects transcription (Buryskova et al., 2004;Werman et al., 2004).
Both IL-1α and IL-1β are ﬁrst synthesized as precursor proteins
that can be enzymatically cleaved. The precursor form of IL-1β
is not biologically active and requires cleavage to elicit its inﬂam-
matory activity. In comparison, the precursor form of IL-1α is
biologically active. However, under certain poorly deﬁned situa-
tions, precursor IL-1α can also be cleaved by the calcium-activated
protease calpain to release the N-terminal propiece and produce
the mature form of IL-1α. The secreted mature form of IL-1α can
then bind IL-1R to induce inﬂammation. Why IL-1 exists in three
different biologically active forms is an important question in the
ﬁeld. Furthermore, the discrete roles of each form of IL-1α (pre-
cursor, propiece, andmature) in disease progression remains to be
formally addressed.
Under homeostatic conditions cells typically undergo apop-
totic cell death, which does not provoke inﬂammation. However,
cellular stress that occurs in response to trauma, hypoxia, chem-
ical and environmental insults, and complement-mediated lysis
can promote necrotic cell death. During programmed apopto-
sis IL-1α is trafﬁcked to the nucleus to prevent its release into
the extracellular compartment (Cohen et al., 2010). In contrast,
necrosis is associated with the release of IL-1α, which then acts
on macrophages, neutrophils, and parenchymal cells to trigger
production of IL-6, TNFα, KC, G-CSF, and other inﬂammatory
mediators (Figure 3). The passive secretion of IL-1α by necrotic
cells following trauma or sterile insults orchestrates the recruit-
ment of neutrophils and macrophages to the site of injury where
they are needed to sequester the injurious agent, remove the
dead cells, and initiate the healing process (Chen et al., 2007;
Eigenbrod et al., 2008). However, exacerbated IL-1α release leads
to pathogenic neutrophilic responses and collateral tissue damage,
and thus is centrally involved in disease progression.
A recent report also suggested that IL-1α is secreted in a
caspase-1 dependent fashion (Gross et al., 2012). They showed that
processed IL-1α is secreted in high amounts following stimulation
with various inﬂammasome activators. Intriguingly, caspase-1
catalytic activity was not required for IL-1α secretion in these
scenarios. In the future it will be important to deﬁne the phys-
iological relevance of catalytic independent caspase-1-mediated
IL-1α release in vivo. Regardless, it is clear that a more complete
understanding of the cellular andmolecular pathways that regulate
IL-1α processing and secretion is critically needed. These ﬁnd-
ings will aid in the design of novel autoinﬂammatory therapeutics
and also provide insight into the etiology of sterile inﬂammatory
diseases.
IL-33
Interleukin-33 is a newly described member of the IL-1 fam-
ily that is predominantly expressed by non-hematopoietic cells
including endothelial and epithelial cells (Moussion et al., 2008).
Similar to IL-1α, IL-33 has also been characterized as a dual func-
tion cytokine that can exert transcriptional activity in the nucleus
(Carriere et al., 2007). Originally it was thought that caspase-1
is required for the processing and secretion of IL-33, however,
it was later found that active IL-33 release occurs independently
of capsase-1 (Talabot-Ayer et al., 2009). Paradoxically, it has been
formally shown that full-length IL-33 is fully bioactive and that
caspase-mediated cleavage of IL-33 actually results in its inactiva-
tion (Cayrol and Girard, 2009; Luthi et al., 2009). Release of IL-33
is believed to occur passively during cell death (Luthi et al., 2009;
Talabot-Ayer et al., 2009).
Interleukin-33 signals through the ST2 receptor, which is abun-
dantly expressed on Th2 cells, mast cells, and most other immune
cell populations (Ali et al., 2007; Chackerian et al., 2007). Stimula-
tion of Th2 cells with IL-33 induces secretion of the Th2 cytokines
IL-4, IL-5, and IL-13 (Schmitz et al., 2005). In a similar fash-
ion, IL-33 has also been shown to drive potent production of Th2
cytokines by type 2 innate lymphoid cells (ILCs; Spits andCupedo,
2012). Furthermore, engagement of ST2 by IL-33 on mast cells
has been suggested to centrally contribute to anaphylactic shock
by triggering the production of proinﬂammatory cytokines and
degranulation (Pushparaj et al., 2009).
ROLE FOR IL-1 FAMILY CYTOKINES IN STERILE
INFLAMMATORY DISEASES
NEURODEGENERATIVE DISEASE
Interleukin-1 is a potent neurotropic cytokine that has been
implicated in numerous neurodegenerative diseases including
Alzheimer’s disease (AD), stroke, Parkinson’s disease, and amy-
otrophic lateral sclerosis (ALS; Allan et al., 2005). These diseases
are typically associated with elevated local and systemic levels of
IL-1. Furthermore, IL-1 can cause neuronal cell injury, breakdown
of the blood–brain barrier, and astrogliosis (Shaftel et al., 2008).
In the case of AD, ﬁbrillar peptide amyloid-β (Aβ) accumulation
that accompanies dementia and neuronal cell death was found to
incite NLRP3 inﬂammasome-dependent IL-1β production (Halle
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FIGURE 3 | Necrotic cells trigger sterile inflammation. Necrotic cells
potently induce sterile inﬂammation through multiple mechanisms. IL-1α
that is released from necrotic cells induces the generation of cytokines and
chemokines that are associated with granulopoiesis and neutrophil recruitment
(G-CSF, KC, IL-6, etc.). In addition, multiple danger-associated molecular
pattern molecules (DAMPs) including uric acid, reactive oxygen species
(ROS), and ATP are released during necrosis and can promote the expression
of factors that are involved in inﬂammation and neutrophil recruitment.
et al., 2008). Genetic deletion of NLRP3/caspase-1/IL-1β axis
molecules markedly attenuated the production of proinﬂamma-
tory cytokines and neurotoxic factors in responses to Aβ, and also
abrogated microglia activation in the brain. Genetic studies have
also recently identiﬁed the Il33 gene as a potential genetic determi-
nant of AD (Chapuis et al., 2009). In this study they show that Il33
expression is markedly reduced in AD patients. Intriguingly, they
demonstrate that IL-33 overexpression hinders the production of
Aβ. Additional studies are needed to follow-up on this exciting link
and also to deﬁne how IL-33 mechanistically limits Aβ secretion.
Recent advancements in IL-1 cytokine family biology have also
uncovered important roles for these proinﬂammatory mediators
in both ALS and Parkinson’s disease. The most common genetic
cause of ALS is dominant gain of function mutations in superox-
ide dismutase 1 (SOD1). Recently it was described that mutant
SOD1 accelerates ALS pathogenesis through the induction of
inﬂammasome-derived IL-1β (Meissner et al., 2010). In the case
of Parkinson’s disease, polymorphisms in Il1β are associated with
exacerbated neuropathology, and IL-1β was found to increase the
rates of dopamine neuron degeneration in a Parkinson’s disease
mouse model (McGeer et al., 2002; Koprich et al., 2008).
Ischemic or hemorrhagic conditions that are responsible for
strokes result in the rapid induction of proinﬂammatory cytokines
and inﬂammatory cells. The initiation of this inﬂammatory
cascade ultimately causes neuronal cell death and functional
impairment. IL-1 expression is one of the most highly up-
regulated factors in stroke patients, thus randomized clinical trials
using IL-1R antagonist (anakinra) to treat acute stroke were con-
ducted (Rothwell et al., 1997; Wang et al., 1997; Emsley et al.,
2005). Strikingly, stroke patients treated with anakinra exhibited
reduced proinﬂammatory cytokine levels and improved cognitive
functions.
Collectively, these ﬁndings highlight a critical role for
inﬂammasome-induced inﬂammation and tissue damage in var-
ious neurodegenerative diseases. Moreover, they have helped to
improve our understanding of the etiology of neurodegenera-
tive disorders and have uncovered novel pathways to target in the
treatment of these debilitating diseases.
PULMONARY DISEASE
The lung is constantly exposed to a multitude of airborne pollu-
tants. Deposition of environmental or man-made irritants in the
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lung is known to cause ﬁbrosis and extensive cellular inﬁltration.
Prolonged damage can ultimately result in devastating pulmonary
disease. IL-1R signaling has emerged as a crucial regulator of many
irritant-induced lung diseases. For instance, IL-1R deﬁcient mice
are highly resistant to lung damage in a myriad of chemically
induced pulmonary disease models (Gasse et al., 2007). In these
studies, disruption of IL-1 signaling was shown to attenuate proin-
ﬂammatory cytokine production, immune cell recruitment, and
ﬁbrosis in response to a variety of irritants including bleomycin,
cigarette smoke, diesel fuel, silica, and asbestos (Cassel et al.,
2008; Hornung et al., 2008; Wilson et al., 2010; Yazdi et al., 2010).
Moreover, it was clearly demonstrated that NLRP3 is a primary
sensor of airborne pollutants in the lung. Indeed, asbestos and
silica potently induce inﬂammasome activation and IL-1β secre-
tion following NLRP3 recognition. Aerosolized asbestos-exposure
in NLRP3 deﬁcient mice resulted in diminished recruitment of
inﬂammatory cells to the lung and concomitant reductions in
proinﬂammatory cytokines (Dostert et al., 2008). Collectively,
work in this ﬁeld suggest that IL-1 blocking therapeuticsmay prove
beneﬁcial in the treatment of asbestos-induced mesothelioma,
silicosis, and potentially other chronic obstructive pulmonary
diseases (COPD).
Important roles for IL-33 in airway inﬂammation have also
been recently described. In particular, IL-33 has been found to
pivotally contribute to asthma-induced pathology. Expression of
IL-33 is highly up-regulated in the lungs of asthmatic patients
and in mouse models of asthma (Kurowska-Stolarska et al., 2008;
Prefontaine et al., 2009). Damage to epithelial cells lining the air-
ways is believed to be the major source of IL-33 that triggers
asthmatic ﬂares (Schmitz et al., 2005). IL-33 release promotes the
recruitment of dendritic cells, Th2 cells, eosinophils, andmast cells
into the airways and ultimately results in Th2-mediated inﬂamma-
tion (Liew et al., 2010; Borish and Steinke, 2011). Direct injection
of IL-33 into the lungs of mice has been shown to rapidly in-
duce eosinophilic inﬂammation and airway-hyperresponsiveness
(AHR; Kondo et al., 2008; Kurowska-Stolarska et al., 2008). Fur-
thermore, in the ovalbumin (OVA)-induced mouse model of
airway inﬂammation, IL-33 causes exacerbated lung damage and
inﬂammatory cell inﬁltration (Kurowska-Stolarska et al., 2008).
Treatment of OVA-induced AHR mice with ST2 and IL-33 block-
ing antibodies was also found to ameliorate airway inﬂammation,
which highlights the great promise that IL-33 neutralizing thera-
pies hold in the treatment of asthma (Lohning et al., 1998; Coyle
et al., 1999; Liu et al., 2009).
ATHEROSCLEROSIS
Atherosclerosis is an inﬂammatory disorder that occurs when fats
and cholesterol accumulate around the arterial walls and cause
disruptions in blood ﬂow and heart failure. Numerous lines of
clinical data point to instrumental roles for IL-1 family molecules
in the induction and progression of atherosclerosis. For instance,
the expression of IL-1β and IL-1R are markedly up-regulated in
arterial plaques, and expression levels are linked to disease sever-
ity (Moyer et al., 1991; Galea et al., 1996). Moreover, circulating
IL-18 levels can be utilized to predict the risk of atherosclerosis-
related death in patients (Mallat et al., 2001; Blankenberg et al.,
2002). Recently, the NLRP3 inﬂammasome has been identiﬁed as
a central regulator of atherosclerosis pathogenesis. It was shown
that cholesterol crystals incite NLRP3 inﬂammasome activation
and subsequent IL-1β and IL-18 secretion (Duewell et al., 2010).
Important roles for inﬂammasomes have also been established
in other mouse models of atherosclerosis. For example, LDL-
receptor-deﬁcient mice (genetically prone to atherosclerosis) that
are reconstituted with bone marrow cells from mice that lack
NLRP3, ASC, or IL-1β are remarkably resistant to plaque for-
mation (Duewell et al., 2010). The apolipoprotein E (APOE)
mouse model is also routinely utilized to study the events that
are responsible for atherosclerosis pathogenesis. APOE deﬁcient
mice on a high fat diet (HFD) develop severe hypercholesterolemia
and arterial plaques around the heart. Interestingly, blockade of
IL-1 signaling by treatment with IL-1R antagonists or genetic
ablation of IL-1R results in marked resistance to the develop-
ment of atherosclerosis in the APOE model (Chi et al., 2004).
These ﬁndings suggest that IL-1 contributes to HFD-induced
arterial plaque formation. However, a recent study also found
that genetically crossing APOE mice to mice that lack NLRP3
does not diminish the severity or incidence of atherosclerosis
(Menu et al., 2011). It remains unclear why these two differ-
ent mouse models of atherosclerosis have produced opposite
ﬁndings in regards to the role of the NLRP3-inﬂammasome in
cardiovascular inﬂammation. Therefore, additional studies are
needed to formally elucidate the role of IL-1 in atherosclerosis
models.
In contrast to the pathogenic role of IL-1 and IL-18 in
atherosclerosis pathogenesis, IL-33 has been described to attenuate
cardiovascular inﬂammation and plaque formation (Miller et al.,
2008). Administration of IL-33 to APOE deﬁcient mice promotes
the induction of Th2-associated cytokines (IL-4, IL-5, and IL-13)
that play a protective role in atherosclerotic plaque formation.
Furthermore, IL-33 treatment also limits plaque development and
cardiovascular disease by promoting the production of atheropro-
tective anti-oxidized low-density lipoprotein (oxLDL) antibodies
and limitingmacrophage foam cell maturation (Miller et al., 2008;
McLaren et al., 2010).
ISCHEMIA-INDUCED INFLAMMATION
Disruption in blood ﬂow to organs causes aberrant cell death and
is responsible for triggering ischemia-associated disease. Inﬂam-
mation arises due to aberrant cell death and hypoxia in the organ.
Myocardial infarction, hypoglycemia, hypotension, and surgery
can trigger ischemia-induced inﬂammation and tissue damage.
Altered IL-1 signaling has been identiﬁed to be a major culprit
in the pathology of many ischemia-related diseases (Boutin et al.,
2001; Thornton et al., 2010). Indeed, massive production of both
IL-1α and IL-1β occurs during ischemia, and blockade of IL-1
signaling can signiﬁcantly attenuate tissue damage and cytokine
production (Shito et al., 1997; Pomerantz et al., 2001; Abbate et al.,
2008; Luheshi et al., 2011). The release of the major alarmin
molecule, IL-1α, following necrosis and hypoxia-induced cell
death is a crucial initiating step of the ischemia-induced inﬂam-
matory cascade (Chen et al., 2007). In contrast, inﬂammasome-
mediated IL-1β production by macrophages is believed to play
important roles in sustaining local inﬂammation later in the
response (Rider et al., 2011).
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Recently emerging data suggests that IL-33 plays a protec-
tive role during ischemia-induced inﬂammation. IL-33 is highly
expressed in both mice and humans following myocardial infarc-
tion, and studies utilizing mice that are deﬁcient in ST2 suggest
that IL-33 limits tissue destruction that results from myocardial
infarction (Weinberg et al., 2002; Sanada et al., 2007; Seki et al.,
2009). Soluble ST2 levels also directly correlate with impaired left
ventricular function post myocardial infarction and thus circulat-
ing ST2 levels has been proposed as a biomarker for heart failure
(Weinberg et al., 2003).
JOINT AND BONE DISEASE
Chronic inﬂammatory bone and joint diseases can cause debil-
itating pain, physical impairments, and signiﬁcant morbidity.
Importantly, the rates of these diseases are projected to rise
substantially in coming years due to increased life expectancies,
sedentary lifestyles, and the ongoing obesity epidemic. IL-1 can
affect various aspects of bone and joint integrity, and as a result IL-
1 is critically involved in the pathogenesis of rheumatoid arthritis
(RA), periodontal disease, osteoarthritis, and gout (Walsh et al.,
2006; Takayanagi, 2007; Jones et al., 2011). For instance, IL-1
stimulates bone resorption bone by directly impinging on osteo-
clast and osteoblast functions (Nguyen et al., 1991; Kwan Tat et al.,
2004). On the other hand, IL-1 signaling contributes to cartilage
deterioration by impairing chondrocyte proteoglycan synthesis
and stimulating the production of joint damaging mediators such
as matrix metalloproteinases and nitric oxide (Joosten et al., 2004;
Zwerina et al., 2007). In the case of RA, insufﬁcient levels of thenat-
urally occurring IL-1R antagonist in the synovium are associated
with joint pathology (Firestein et al., 1994). Treatment of RA with
IL-1 pathway inhibitors has achievedmoderate clinical success and
is currently prescribed to limit the progression of joint damage in
individuals withmoderate to severe RA (Arend et al., 1998; Bresni-
han et al., 1998). Similar to RA, dysregulated IL-1-mediated events
also impinge on the development of osteoarthritis; however, ther-
apeutic targeting of IL-1 has only provided modest improvements
in clinical trials (Chevalier et al., 2009).
Gout and pseudogout are sterile inﬂammatory disorders that
occur when monosodium urate (MSU) or calcium pyrophos-
phate dihydrate (CPPD) crystals, respectively, deposit in the joints
and periarticular tissue. These crystalline agents cause aggravated
inﬂammation and neutrophil recruitment that can result in bone
and joint damage. This sterile inﬂammatory response is depen-
dent on NLRP3 inﬂammasome activation both in vitro and in
vivo (Martinon et al., 2006). Moreover, colchicine, which is com-
monly used to treat gout and pseudogout, was found to dampen
inﬂammasome-triggered IL-1β production. Currently, inhibition
of crystal uptake is targeted to treat gout, however, this recent
data suggests that addition of IL-1R blockade could substantially
improve current therapeutics.
Excessive Th1- and Th17-mediated inﬂammatory responses
have traditionally been associated with joint destruction, espe-
cially in the case of arthritis. IL-33 has been extensively shown
to potently induce Th2-driven inﬂammation, and thus it came
as a great surprise that the absence of IL-33-mediated signaling
results in attenuated joint disease (Xu et al., 2008). Appreciable
levels of IL-33 and ST2 can be detected in the synovium of RA
patients (Carriere et al., 2007; Palmer et al., 2009). Furthermore,
the disruption of ST2 activation, either by genetic abrogation
or antibody-induced blockade, resulted in decreased joint dis-
ease in the mouse model of collagen-induced arthritis (CIA; Xu
et al., 2008; Palmer et al., 2009). The lack of functional ST2 con-
tributed to protection in this model through the dampening of
inﬂammatory cytokine and anti-collagen antibody production. In
contrast, treatment of CIA-induced mice with exogenous IL-33
at the onset of disease resulted in exacerbated joint destruction.
Expression of ST2 on mast cells was shown to be critical for
disease pathology in the CIA model, thus suggesting a critical
role for IL-33-mediated activation of mast cells in joint disease
(Xu et al., 2008).
MACULAR DEGENERATION
Age-related macular degeneration (AMD) is the leading cause
of vision loss and blindness in older adults. It is characterized
by the accumulation of protein aggregates – known as drusen
deposits – between the retina and choroid of the eye. Recently,
the importance of inﬂammasome-derived IL-18 in this debilitat-
ing eye disease was described (Doyle et al., 2012; Tarallo et al.,
2012). In one study it was shown that the accumulation of
Alu RNA transcripts that are associated with disease progres-
sion in AMD patients can activate the NLRP3 inﬂammasome
(Tarallo et al., 2012). Using both genetic and pharmacological
inhibition of inﬂammasome components they found that the
NLRP3/ASC/caspase-1 axis and IL-18, in particular, was required
for ocular damage in response to Alu RNA. Intriguingly, they
showed that regulation of inﬂammasome activation in ocular-
speciﬁc epithelial cells and not immune cells was involved in
disease pathology. A separate study also reported critical roles
for inﬂammasome-derived IL-18 in AMD. Their ﬁndings revealed
that drusen droplets isolated from AMD patients incite inﬂam-
masome activation and the subsequent release of IL-1β and IL-18
(Doyle et al.,2012). However, in contrast to theother study,NLRP3
inﬂammasome-induced IL-18 was found to have a protective role
in macular degeneration. It is currently unclear why these two
recent studies have yielded disparate ﬁndings, however, differences
inmousemodels may account for the different outcomes. Regard-
less, it is clear from these studies that inﬂammasome-induced
IL-18 critically regulates ocular damage.
MULTIPLE SCLEROSIS
Interleukin-1 signaling has also been found to play instrumen-
tal roles in the pathogenesis of multiple sclerosis (MS) in animal
models and patients. Mice that are deﬁcient in IL-1R are protected
from the development of neuroinﬂammation and demyelinating
disease in the experimental autoimmune encephalomyelitis (EAE)
mouse model of MS. Disruption in IL-1R was shown to con-
fer protection by abrogating the induction of pathogenic CD4+
T cells and γδ T cells (Matsuki et al., 2006; Sutton et al., 2006;
Chung et al., 2009). Moreover, IL-1R−/− mice exhibit marked
reductions in IL-17 and GM-CSF production (Sutton et al., 2009;
Lukens et al., 2012). Genetic ablation of caspase-1 provided signif-
icant protection during the early phase of the response, however,
inﬂammasome deﬁciency did not lead to the same levels of pro-
tection as seen in mice that lack IL-1R (Gris et al., 2010; Shaw
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et al., 2010; Inoue et al., 2012a). This suggests that inﬂammasome-
independent sources of IL-1 are also important in the pathogenesis
of EAE. Future studies are needed to further characterize these
sources of IL-1 in neuroinﬂammatory disease.
IFN-β is routinely prescribed to treat MS and the mode of
action of this therapy was recently described to involve inhi-
bition of inﬂammasome-mediated IL-1β production (Guarda
et al., 2011a). Interestingly, one-third of MS patients do not
respond to this regimen (Inoue et al., 2012b). It is possible that
inﬂammasome-independent sources of IL-1β drive neuroinﬂam-
mation inMSpatients that are non-responsive to IFN-β. Strategies
that inhibit inﬂammasome-independent IL-1 generationmayhold
great promise for the treatment of MS in this group of patients.
Both protective and pathogenic roles have been recently
assigned to IL-33 in EAE. In one study, it was found that genetic
abrogation of ST2 promotes exacerbated neuroinﬂammation
(Jiang et al., 2012). They suggest that IL-33 provides neuropro-
tection by dampening IL-17 and IFN-γ production, and also by
promoting the induction of alternatively activated macrophages
that possess suppressive functions. Another study, on the other
hand, showed that blockade of IL-33 during the induction phase
can limit the development of demyelinating disease by curtailing
the expression of pathogenic cytokines (Li et al., 2012). Both stud-
ies agree that IL-33 and its receptor, ST2, are highly expressed in
the central nervous system (CNS) of EAE mice. Additional stud-
ies on the role of IL-33 in EAE are thus needed to clarify these
disparate results.
OBESITY AND METABOLIC SYNDROME
The incidence of obesity worldwide has increased at a staggering
rate in recent decades and as a result the obesity epidemic has
become a major threat to global human health. Obesity is associ-
ated with increased rates of type 2 diabetes, atherosclerosis, and
joint disease. Current strategies to combat obesity that include
lifestyle and dietary changes have been unsuccessful in curtail-
ing the obesity epidemic. Thus, therapies that target the speciﬁc
molecular pathways that promote obesity-related diseases are des-
perately needed and are at forefront of biomedical investigation.
Immune cell-mediated inﬂammation is now recognized to con-
tribute to the development and progression of obesity (Gregor
and Hotamisligil, 2011; Osborn and Olefsky, 2012).
Extensive research has shown that IL-1 family cytokines drive
the development of obesity and related diseases. Of note, obesity
progression in both diet-induced and genetically prone obesemice
coincided with enhanced caspase-1 and IL-1β activity (Stienstra
et al., 2010; Vandanmagsar et al., 2011). Importantly, genetic and
pharmacological abrogation of the inﬂammasome was demon-
strated to lower obesity-associated inﬂammation and improve
insulin-sensitivity in HFD fed mice (Masters et al., 2010; Stien-
stra et al., 2010, 2011; Vandanmagsar et al., 2011;Wen et al., 2011).
During obesity the adipose tissue undergoes considerable expan-
sion and remodeling to store excess energy in the form of fat
(Shoelson et al., 2006). Differentiation of adipocytes during adi-
pose tissue expansion is associatedwith the activation of caspase-1,
and IL-1β has been reported to convert adipocytes into a more
insulin-resistant phenotype (Stienstra et al., 2010). Furthermore,
hypertrophic and hyperplastic changes that occur during weight
gain are typically associated with increased cell death and the
release of cell death-related stimuli (ATP, uric acid, ROS, and dam-
age mitochondria) in metabolic tissue can trigger inﬂammasome
activation and enhanced secretion of IL-1β and IL-18 (Strissel
et al., 2007; Khan et al., 2009).
Saturated fatty acids and other obesity-related metabolites
that are markedly elevated in obese individuals have long been
suspected to contribute to inﬂammation and disease pathol-
ogy. However, the mechanistic link connecting metabolic factors
derived from HFDs to chronic inﬂammation and insulin resis-
tance remained elusive for many years. A collection of recent
studies have identiﬁed the NLRP3 inﬂammasome as a central
sensor that detects obesity-related stress signals and that triggers
IL-1β production and subsequent disease pathogenesis (Masters
et al., 2010; Stienstra et al., 2010, 2011; Vandanmagsar et al., 2011;
Wen et al., 2011; Henao-Mejia et al., 2012). Speciﬁcally, it was dis-
covered that saturated fatty acids (i.e., palmitate and ceramide)
elicit NLRP3 inﬂammasome activation and subsequent release of
IL-1β and IL-18 (Vandanmagsar et al., 2011; Wen et al., 2011).
It is believed that saturated fatty acids disrupt AMPK signaling,
which results in defective autophagy and the accumulation of
dysfunctional mitochondria and ROSs. ROS production is a well-
established activator of the NLRP3 inﬂammasome and thus the
accumulation of ROS in response to fatty acid-induced impair-
ment of autophagy is believed to be responsible for inﬂammasome
activation in this setting (Zhou et al., 2009; Wen et al., 2011). Col-
lectively these ﬁndings have provided us with important insight
into the immunological underpinnings of obesity and deﬁne piv-
otal roles for the NLRP3 inﬂammasome in obesity-induced sterile
inﬂammation.
TYPE 2 DIABETES
Type 2 diabetes mellitus (T2DM) is an obesity-related inﬂamma-
tory disorder characterized by insulin resistance and uncontrolled
glucose levels. It has become increasing clear that inﬂammasome-
derived cytokines centrally regulate many of the inﬂammatory
processes that are responsible for the impairment of metabolic
function and the insulin resistance that underlies T2DM. For
example, IL-1β can cause apoptosis of insulin-producing β-cells
in the pancreas and also promotes insulin resistance in adipocytes
(Bendtzen et al., 1986; Lagathu et al., 2006). Moreover, IL-18 is
up-regulated in T2DM patients and has been linked to increased
secondary renal failure and atherosclerosis (Blankenberg et al.,
2002; Thorand et al., 2005). Perhaps the best example of the con-
tribution of IL-1 family cytokines in the pathogenesis of T2DM
comes from the recent clinical success of IL-1R antagonists in the
treatment of this chronic disease (Larsen et al., 2007). In these clin-
ical trials, IL-1 signaling inhibition was found to stabilize blood
glucose levels and improve β-cell function.
Intriguingly, islet amyloid polypeptide (IAPP), was recently
discovered to stimulate inﬂammasome activation and exacerbate
T2DM (Masters et al., 2010). IAPP is a metabolite secreted at the
same time as insulin by β-cells in the pancreas. IAPP forms amy-
loid deposits in the pancreas during T2DMprogression (Wei et al.,
2011). This formation of amyloid plaques is a salient hallmark
of T2DM and has been speculated to inﬂuence disease severity.
Recent ﬁndings now identify that IAPP amyloid plaques impinge
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on T2DM pathogenesis by activating the NLRP3 inﬂammasome
and triggering the secretion of IL-1β.
FUTURE PERSPECTIVES AND CONCLUSIONS
Recent discoveries have identiﬁed IL-1 family cytokines as piv-
otal regulators of a spectrum of sterile inﬂammatory diseases.
The effectiveness of IL-1R blockade in the treatment of T2DM
and other diseases suggest that additional therapeutics that tar-
get IL-1 family cytokines may provide effective strategies to treat
other devastating inﬂammatory disorders. The identiﬁcation of
the central role of IL-1-associated cytokines in inﬂammatory
disease progression and the discovery of the speciﬁc danger
signals that trigger inﬂammation has provided an important foun-
dation in our understanding of the etiology of many human
diseases. Despite these recent advancements, numerous impor-
tant questions remain to be addressed in order to gain a more
complete understanding of the role of IL-1 family cytokines in
non-communicable chronic diseases.
For example the ability of inﬂammasomes to inﬂuence autoin-
ﬂammatory pathogenesis in cell types other thanmacrophages and
dendritic cells has not been studied in detail. Multiple immune
and organ-speciﬁc cell types express NLRs and inﬂammasome-
associated proteins (Guarda et al., 2011b; Kufer and Sansonetti,
2011). Investigation of their contribution to disease should pro-
vide novel insight. Furthermore, up to now our understanding of
the role of inﬂammasomes in sterile inﬂammatory disease has
been limited to ﬁndings generated from studying the NLRP3
inﬂammasome. Much of this can probably be attributed to the
unique role that the NLRP3 inﬂammasome plays in sensing mul-
tiple different stress and danger signals. However, multiple new
NLR–inﬂammasome complexes have been discovered in recent
years. Evaluation of the involvement of the AIM2, caspase-11,
and caspase-8 inﬂammasomes in sterile inﬂammatory disorders is
a very exciting area of future investigation (Maelfait et al., 2008;
Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Kayagaki
et al., 2011; Gringhuis et al., 2012; Vince et al., 2012). We also still
lack a complete understanding of the regulatory pathways and
molecules that help to dampen excessive IL-1-mediated events.
Identiﬁcation of key molecules and regulatory networks that facil-
itate in suppressing IL-1-induced inﬂammation is paramount
to the identiﬁcation of improved therapeutics to treat sterile
inﬂammatory diseases.
Investigation of the role of commensal bacteria in sterile
inﬂammatory disease is another burgeoning frontier in this
ﬁeld. Although by deﬁnition sterile inﬂammation diseases are
non-communicable in the infectious sense, it has become appar-
ent recently that gut microﬂora can shape sterile inﬂammatory
responses. Gut commensal bacteria are involved in calibrating the
activation threshold of both adaptive and innate immune cells
(Abt et al., 2012; Hooper et al., 2012). Moreover, lipopolysaccha-
ride that translocates from the gut has been reported to directly
inﬂuence both obesity and cardiovascular disease (Michelsen et al.,
2004; Henao-Mejia et al., 2012).
Recent advancements in the ﬁeld of IL-1 biology have greatly
enhanced our understanding of the etiology of numerous autoin-
ﬂammatory disorders. These studies have positioned IL-1 family
cytokines as central regulators that link cellular stress that results
fromdanger/stress signals to the induction andprogression of ster-
ile inﬂammatory diseases. These ﬁndings and future discoveries in
the IL-1 ﬁeld should provide novel strategies in the treatment of
autoinﬂammatory diseases.
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